bioAffinity Technologies (BIAF) vs Medpace (MEDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Medpace is the larger company by market cap ($17.08 billion vs $5.5 million), about 3099.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIAF | MEDP |
|---|---|---|
| Share price | $4.73 | $612.05 |
| Market cap | $5.51M | $17.08B |
| 1-day change | -16.22% | +1.55% |
| YTD return | — | +8.97% |
| 1-year return | — | +18.00% |
| 5-year return | — | +227.16% |
| P/E ratio (TTM) | — | 35.94 |
| Forward P/E | — | 31.69 |
| EPS (TTM) | $-109.35 | $17.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.53B |
| Revenue growth (YoY) | — | +19.97% |
| Net income (latest FY) | — | $451.12M |
| Operating margin | — | 21.14% |
| Net margin | — | 17.83% |
| 52-week high | $80.70 | $677.90 |
| 52-week low | $4.56 | $373.00 |
| Distance from 52-week high | -94.14% | -9.71% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | -3.30% |
| Average volume | 3.73M | 273.89K |
| Shares outstanding | 1.17M | 27.91M |
| Employees | 57 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medpace is about 3099.1 times larger than bioAffinity Technologies by market value ($17.08B vs $5.51M).
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
BIAF vs MEDP FAQ
Which is bigger, bioAffinity Technologies or Medpace?
Medpace (MEDP) is larger, with a market capitalization of $17.08B compared with $5.51M for bioAffinity Technologies (BIAF).
Are bioAffinity Technologies and Medpace in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.